Dr Rodriguez on a Case Study of EGFR-Mutated NSCLC
Estelamari Rodriguez, MD, MPH, discusses a case study of a patient with non–small cell lung cancer harboring an EGFR L858R mutation and a TP53 mutation.
Related Articles
2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer
Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.
Bladder Cancer Care Shifts as BCG Shortage Lingers, With Investigative Combinations and Tools at the Forefront
Vikram M. Narayan, MD, details updates in the bladder cancer field, including effects of the BCG shortage and upcoming therapies/tools of interest.
Survival Outcomes in Patients With ERBB2-Positive Metastatic Breast Cancer With CNS Involvement
Patients with ERBB2-positive breast cancer and central nervous system (CNS) metastases only vs concomitant extracranial metastases have been found to experience longer overall survival but…
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
ICR welcomes NICE recommendation of olaparib for advanced breast cancer
February 2025 decisions news release
10 February 2025 The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, February 10) published advice…
Acalabrutinib Plus Venetoclax/Obinutuzumab Demonstrates Efficacy, Safety in Mantle Cell Lymphoma
Acalabrutinib plus venetoclax and obinutuzumab demonstrated antitumor activity with a manageable safety profile in mantle cell lymphoma.
Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment
Nature Reviews Cancer – In this Review, Polak, Zhang and Kuo discuss the currently available and rapidly evolving 3D tumour organoid models that capture the…
Alerts | American Association for Cancer Research
Alerts | American Association for Cancer Research .main-content h1 { font-weight: 300; color: #44b13e; margin-bottom: 0; } .main-content h3 { margin-bottom: 16px; } .main-content h3…
Asciminib for Ph+ ALL: a step forward?
In this issue of Blood, Luskin et al present results of the first phase 1 trial combining asciminib, an allosteric BCR::ABL1 inhibitor, with the tyrosine k
Spring Group Meeting: Shorter, But Sweeter | SWOG
We have consolidated our group meeting schedule from four days to three, starting in spring of 2025. That meeting will run Thursday to Saturday, May…
